tiprankstipranks
Trending News
More News >
Cantargia AB (SE:CANTA)
:CANTA

Cantargia AB (CANTA) Price & Analysis

Compare
0 Followers

CANTA Stock Chart & Stats


Financials

CANTA FAQ

What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.00 and its highest was kr5.08 in the past 12 months.
    What is Cantargia AB’s market cap?
    Cantargia AB’s market cap is €277.45M.
      When is Cantargia AB’s upcoming earnings report date?
      Cantargia AB’s upcoming earnings report date is Aug 21, 2025 which is in 69 days.
        How were Cantargia AB’s earnings last quarter?
        Cantargia AB released its earnings results on May 13, 2025. The company reported -kr0.189 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.189.
          Is Cantargia AB overvalued?
          According to Wall Street analysts Cantargia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Cantargia AB pay dividends?
            Cantargia AB does not currently pay dividends.
            What is Cantargia AB’s EPS estimate?
            Cantargia AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Cantargia AB have?
            Cantargia AB has 248,611,650 shares outstanding.
              What happened to Cantargia AB’s price movement after its last earnings report?
              Cantargia AB reported an EPS of -kr0.189 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.783%.
                Which hedge fund is a major shareholder of Cantargia AB?
                Currently, no hedge funds are holding shares in SE:CANTA

                Company Description

                Cantargia AB

                Cantargia AB (CANTA) is a biotechnology company based in Sweden, focusing on the research and development of antibody-based treatments for various cancer types and autoimmune diseases. The company utilizes its proprietary technology platform to develop innovative therapies targeting specific molecular pathways involved in disease progression. Cantargia's lead product candidate, nadunolimab (CAN04), is an antibody therapy currently undergoing clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer.
                Similar Stocks
                Company
                Price & Change
                Follow
                Oncopeptides AB
                Guard Therapeutics International AB
                Immunicum AB
                Isofol Medical AB
                Xbrane Biopharma AB
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis